TY  - JOUR
T1  - THe evolution of influenza resistance and treatment
AU  - Weinstock DM, Zuccotti G
Y1  - 2009/03/11
N1  - 10.1001/jama.2009.324
JO  - JAMA
SP  - 1066
EP  - 1069
VL  - 301
IS  - 10
N2  - 
In February 2006, the US Centers for Disease Control and Prevention (CDC) reported that 92.3% of the circulating influenza A(H3N2) at that time was resistant to the adamantanes (amantadine and ramantidine), 1 of 2 pharmacological classes available for the treatment of influenza.1 The resistant viruses harbored an S31N amino acid substitution in the influenza M2 protein that confers resistance but does not affect virulence. Although resistance to adamantanes increased to 14.5% in the prior year,2 the dramatic increase in 2005-2006 came as a shock to both the medical and scientific communities and the public.3

SN  - 0098-7484
M3  - doi: 10.1001/jama.2009.324
UR  - http://dx.doi.org/10.1001/jama.2009.324
ER  -